TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis

Current Rheumatology Reports

Volumn 14, Issue 6, 2012, Pages 501-508

  Silva, Francisco ^a   Cisternas, Marcela ^a   Specks, Ulrich ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b MAYO CLINIC   (United States)

Author keywords

Adalimumab; ANCA associated vasculitis; Biologicals; Cancer; Etanercept; Infliximab; Malignancy; Risk; Solid malignancy; Therapy; TNF blockers; Treatment; Vasculitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANCA ASSOCIATED VASCULITIS; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; BILE DUCT CARCINOMA; BLADDER CARCINOMA; BREAST CARCINOMA; BRONCHUS CARCINOID; CANCER RISK; CLINICAL TRIAL (TOPIC); COLON ADENOCARCINOMA; CROHN DISEASE; DRUG WITHDRAWAL; GRANULOMATOSIS WITH POLYANGIITIS; HEMATOLOGIC MALIGNANCY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY CARCINOMA; LIPOSARCOMA; LYMPHOMA; MELANOMA; META ANALYSIS (TOPIC); NONHODGKIN LYMPHOMA; PROGNOSIS; PROSTATE CANCER; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SMALL INTESTINE CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THYMOMA; TONSIL CARCINOMA; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; HUMANS; IMMUNOGLOBULIN G; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WEGENER GRANULOMATOSIS;

EID: 84869229690     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0290-2     Document Type: Review

References (55)

1. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987; 316(7): 379-85. (Pubitemid 17034263)
2. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008; 67(5): 625-30. (Pubitemid 351571925)
3. Comarmond C, Plaisier E, Dahan K, et al. Anti TNF-alpha in refractory Takayasu's arteritis: Cases series and review of the literature. Autoimmun Rev. 2012; 11(9): 678-84. This case series literature review is the most recent evaluation of TNF-α blockers in Takayasu arteritis. A total of 84 patients with immunosuppressive drugs refractory disease treated with TNF- α blockers were reviewed (infliximab and etanercept). Complete and partial remissions were achieved in 37% and 53% of cases, respectively.
4. Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011; 41(1): 61-70. This recent case series literature review evaluates the use of TNF-α blockers in Behç et's disease.
5. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004; 15(3): 717-21. (Pubitemid 38294802)
6. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006; 54(5): 1608-18.
7. Laurino S, Chaudhry A, Booth A, et al. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant. 2010; 25(10): 3307-14. This Phase II, open-label, prospective trial evaluates the safety and effectiveness of Adalimumab in severe AAV. A total of 14 patients with active severe AAV were evaluated, showing response rates and adverse events were similar to standard therapy alone.
8. Noronha IL, Kruger C, Andrassy K, et al. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int. 1993; 43(3): 682-92. (Pubitemid 23071953)
9. Tesar V, Masek Z, Rychlik I, et al. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant. 1998; 13(7): 1662-7. (Pubitemid 28306791)
10. Kamesh L, Harper L, Savage CO. ANCA-positive vasculitis. J Am Soc Nephrol. 2002; 13(7): 1953-60. (Pubitemid 34700622)
11. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975; 72(9): 3666-70.
12. Sanlioglu AD, Aydin C, Bozcuk H, et al. Fundamental principals of tumor necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma. Lung Cancer. 2004; 44 (2): 199-211. (Pubitemid 38482053)
13. Lejeune FJ, Ruegg C. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment. Bull Cancer. 2006; 93(8): E90-100.
14. Ekstrom K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their firstdegree relatives. Arthritis Rheum. 2003; 48(4): 963-70. (Pubitemid 36418238)
15. Gelfand JM, Berlin J, Van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol. 2003; 139(11): 1425-9. (Pubitemid 37433132)
16. Heymann WR. Side effects of the biologics. J Am Acad Dermatol. 2005; 53(4): 692-3. (Pubitemid 41399940)
17. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004; 50(6): 1740-51. (Pubitemid 38725085)
18. FDA. Arthritis Advisory Committee Briefing Information: Update on the TNF-a Blocking Agents 2003. Available at: http: // www.fda.gov/ohrms/dockets/ac/ 03/briefing/3930b1.htm.
19. Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol. 2006; 33(5): 854-61.
20. FDA. Follow-up to the June 4, 2008 Early Communication about the Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). 2009. Available at : http: //www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm174449.htm.
21. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002; 46(12): 3151-8. (Pubitemid 35453523)
22. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001; 45(6): 953-6. (Pubitemid 33096643)
23. Lebwohl M, Blum R, Berkowitz E, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol. 2005; 141(7): 861-4. (Pubitemid 41058067)
24. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295 (19): 2275-85. (Pubitemid 43736578)
25. Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. A longterm, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis. 2006; 65 (12): 1578-84. (Pubitemid 44799668)
26. Enbrel® (etanercept) for Subcutaneous Injection: prescribing information. Thousand Oaks: Immunex Corporation; 2011. p. 8-9.
27. Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009; 68(7): 1177-83. In this meta-analysis of nine RCT in patients with with rheumatoid arthritis, the risk of malignancy in 2244 participants who received etanercept compared to 1072 participants who received control therapy. Using individual patient data, no statistically significant increase in the risk of malignancy was found with etanercept use.
28. Edgar JD, Rooney DP, McNamee P, et al. An association between ANCA positive renal disease and malignancy. Clin Nephrol. 1993; 40(1): 22-5. (Pubitemid 23221729)
29. Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998; 9(5): 842-52. (Pubitemid 28209094)
30. Knight A, Askling J, Ekbom A. Cancer incidence in a populationbased cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002; 100(1): 82-5. (Pubitemid 34602069)
31. Pankhurst T, Savage CO, Gordon C, et al. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford). 2004; 43 (12): 1532-5. (Pubitemid 39642578)
32. Tatsis E, Reinhold-Keller E, Steindorf K, et al. Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum. 1999; 42(4): 751-6. (Pubitemid 29171996)
33. Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCAassociated vasculitis. Rheum Dis Clin North Am. 2010; 36 (3): 447-61.
34. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J. 1958; 2(5091): 265-70.
35. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116(6): 488-98.
36. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007; 57 (8): 1473-80. (Pubitemid 350308846)
37. Kermani T, Schä fer V, Crowson C, et al. Malignancy Risk in Patients with Giant Cell Arteritis: A Population-Based Cohort Study. Arthritis Care Res. 2010; 62(2): 149-54.
38. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a sixmonth open-label trial to evaluate safety. Arthritis Rheum. 2001; 44 (5): 1149-54. (Pubitemid 32433622)
39. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005; 352(4): 351-61.
40. Silva F, Seo P, Schroeder DR, et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum. 2011; 63(8): 2495-503. This RCT based cohort follow-up study evaluates the 5 years risk of solid malignancies in GPA cases who were treated with etanercept or placebo added to standard therapy.
41. Lafaille P, Bouffard D, Provost N. Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. Arch Dermatol. 2009; 145(1): 94-5.
42. Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies and cyclophosphamide exposure in Wegener's granulomatosis. J Rheumatol. 2008; 35(1): 11-3.
43. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford). 2002; 41(11): 1303-7. (Pubitemid 35363806)
44. Lamprecht P, Arbach O, Voswinkel J, et al. Induction of remission with infliximab in therapy-refractory Wegener's granulomatosis - Follow-up of six patients. Dtsch Med Wochenschr. 2002; 127 (37): 1876-80.
45. Booth AD, Jefferson HJ, Ayliffe W, et al. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis. 2002; 61(6): 559. (Pubitemid 34539105)
46. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti- TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002; 41(10): 1126-32. (Pubitemid 35203539)
47. Aeberli D, Oertle S, Mauron H, et al. Inhibition of the TNFpathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002; 132(29-30): 414-22. (Pubitemid 35303463)
48. Kleinert J, Lorenz M, Kostler W, et al. Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr. 2004; 116(9-10): 334-8. (Pubitemid 38843143)
49. El-Shabrawi Y, Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye (Lond). 2005; 19(9): 1017-8. (Pubitemid 43114989)
50. Fujikawa K, Kawakami A, Eguchi K. Recovery from multiple cranial nerve palsy of Wegener's granulomatosis with infliximab. J Rheumatol. 2008; 35(7): 1471-2. (Pubitemid 352000809)
51. de Menthon M, Cohen P, Pagnoux C, et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol. 2011; 29(1 Suppl 64): S63-71. Prospective randomised multicentre study comparing efficacy and tolerance of infliximab versus rituximab to treat refractory GPA at 1 year. Long term follow-up is also described.
52. Kontkanen M, Paimela L, Kaarniranta K. Regression of necrotizing scleritis in Wegener's granulomatosis after infliximab treatment. Acta Ophthalmol. 2010; 88(3): e96-7.
53. Seror R, Pagnoux C, Ruivard M, et al. Treatment strategies and outcome of induction-refractoryWegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line inductionrefractory disease in the WEGENT trial. Ann Rheum Dis. 2010; 69 (12): 2125-30.
54. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002; 301(2): 418-26. (Pubitemid 34429950)
55. Ciledag A, Deniz H, Eledag S, et al. An aggressive and lethal course of Churg-Strauss syndrome with alveolar hemorrhage, intestinal perforation, cardiac failure and peripheral neuropathy. Rheumatol Int. 2012; 32(2): 451-5. Recent case report using Adalimumab in AAV.